poly(A) binding protein cytoplasmic 1 pseudogene 6Genealiases: []
Q-omics provides the consensus-scored PABPC1P6 profile across patient tissues and cancer cell-line models. PABPC1P6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, PABPC1P6 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, PABPC1P6 RNA expression shows 6,160 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, HNSC, and STAD as cancer lineages where PABPC1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PABPC1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PABPC1P6 survival associations across molecular data types. PABPC1P6 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PABPC1P6 RNA expression–survival associations across cancer types. High PABPC1P6 expression shows unfavorable associations in TGCT, LIHC, CESC and LUSC, but favorable associations in HNSC and ESCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for PABPC1P6 RNA expression.
This table summarizes PABPC1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PABPC1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PABPC1P6 shows higher tumor expression in HNSC. The HNSC box plot shows higher PABPC1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .015).
This table shows molecular features associated with PABPC1P6 in patient tissues and cancer cell lines. In patient samples, PABPC1P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
